[英文,新闻] Forecast Insight: HBV - Baraclude and Viread set to th

StephenW

Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competition  now available at ReportsandReports

Posted for ReportsandReports by shweta on April 26th 2011  and filled under  Other

In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009.

Dallas,  TX: ReportsandReports announce it will carry  Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competition  Market Research Report in its Store. Browse complete Report on: http://www.reportsandreports.com ... iread-set-to-thriv/ Introduction In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries of key drugs such as Baraclude and Viread, and reach approximately $893m by 2019. Scope      * Analysis of the current hepatitis B market dynamics across the US, 5EU, Japan and Turkey, with a snapshot of the Rest of World countries     * Thorough assessment of key marketed products for hepatitis B therapy     * Detailed ten-year sales forecasts for marketed hepatitis B drugs in each of the seven major markets and Turkey     * Review of opinions of key hepatitis B opinion leaders on future market developments Highlights In 2009, small molecule antivirals dominated the hepatitis B market with sales of $954m. In comparison, sales of interferon products were low, accounting for only 3% of total hepatitis B sales in 2009. This low market share can be attributed to the high cost of interferon products, their restricted use and inconvenient mode of administration. Market growth until 2014 will be driven by the strong uptake of newer hepatitis B antivirals such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread (tenofovir). Older products such as Gilead's Hepsera (adefovir) and GlaxoSmithKline's Zeffix (lamivudine) will be used less frequently owing to the increased risk of resistance. In 2009, Baraclude was the best selling brand in terms of value in Turkey; however Zeffix dominated in terms of volume. The popularity of Zeffix can be explained by the stringent reimbursement policy in Turkey, which restricts the use of more expensive drugs such as the pegylated interferons, Baraclude and Viread to specific populations.

(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

预测分析：B型肝炎 - 博路定VIREAD的设置和蓬勃发展，在有限的竞争，现已面临ReportsandReports
由shweta ReportsandReports张贴于2011年4月26日和在其他填充

2009年，乙肝在所列的七大主要市场的销售总额为954米，表明2005年至2009年复合年增长率为37.5％。


达拉斯，得克萨斯州：ReportsandReports宣布它将进行预测分析：B型肝炎 - 博路定VIREAD的设置和蓬勃发展，在有限竞争的市场研究报告其商店的脸。

浏览完整的报告：http://www.reportsandreports.com ... iread-set-to-thriv/

简介

2009年，乙肝在所列的七大主要市场的销售总额为954米，表明2005年至2009年复合年增长率为37.5％。 Datamonitor公司预计该市场将增长到2014年的12亿美元。然而，2015至19年，在所列的七大主要市场的销售额将下滑，因为博路定和等VIREAD的关键药物专利失效，到2019年达到约八百九十三米。

范围

     *分析当前的B型肝炎在美国，5EU，日本和土耳其的市场动态和快照，世界其它地区的国家

    *彻底评估销售的产品主要用于乙肝治疗

    *详细十一年的销售预测，销售的乙型肝炎治疗药物在七个主要市场和土耳其各

    *审查乙肝关键意见领袖对未来市场发展的意见

亮点

2009年，小分子抗病毒药物为主的销售与美元九五四米乙肝市场。相比之下，干扰素产品销售量非常低，只占总额的3％的销售B型肝炎在2009年。这样低的市场份额可能是由于产品成本高的干扰素，其限制使用和管理不方便模式。

市场，直到2014年的增长将推动对新的B型肝炎，如施贵宝的博路定（恩替卡韦）和Gilead公司的VIREAD的（替诺福韦）抗病毒药物强烈的吸收。如Gilead公司的Hepsera（阿德福韦）和葛兰素史克公司的一种口服药片（拉米夫定）老产品将被用于减少由于频繁的抵抗风险增加。

2009年，博路定是在价值计算，土耳其最畅销的品牌，但是一种口服药片在数量上占主导地位。流行的一种口服药片可以被解释为在土耳其严格的报销政策，限制，如聚乙二醇干扰素，博路定和VIREAD的特定人群更昂贵的药物使用。